UnknownNot Applicable

Clinical Study of Umbilical Cord Blood Mononuclear Cell Therapy for the Treatment of Chronic Atrophic Gastritis

China60 participantsStarted 2023-06-07

Plain-language summary

To evaluate the efficacy and safety of umbilical cord blood mononuclear cells in the treatment of chronic atrophic gastritis.

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subjects voluntarily participated in the study and signed an informed consent.
✓. The age is 18-65 years old, regardless of gender.
✓. Patients with chronic atrophic gastritis by gastroscopy and pathological examination.
✓. Patients with a negative C13 breath test or have eradicated Helicobacter pylori infection.
✓. Patients without contraindications to submucosal injection of umbilical cord blood derived mononuclear cells.

✕. Patients with gastric ulcer, erosive gastritis, active upper gastrointestinal bleeding, gastric varices, or other gastric tumors.
✕. Patients who are taking or have taken proton pump inhibitors, antibiotics, glucocorticoids, nonsteroidal anti-inflammatory drugs and immunosuppressants in the last six months.
✕. People who have had gastric surgery or required gastric surgery during the study.
✕. Patients with severe systemic diseases (diseases of cardiovascular, liver, blood, kidneys, lungs or liver).
✕. Pregnant or nursing females.
✕. Patients who are reluctant to accept endoscopy and treatment.

Change from baseline OLGA/OLGIM stages of gastric mucosa

Timeframe: At the first, seventh and thirteenth month of treatment

Change from baseline gastric mucosal status under gastroscope

Timeframe: At the first, seventh and thirteenth month of treatment

NCT IDNCT05808010

SponsorShandong Provincial Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-04

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subjects voluntarily participated in the study and signed an informed consent.
✓. The age is 18-65 years old, regardless of gender.
✓. Patients with chronic atrophic gastritis by gastroscopy and pathological examination.
✓. Patients with a negative C13 breath test or have eradicated Helicobacter pylori infection.
✓. Patients without contraindications to submucosal injection of umbilical cord blood derived mononuclear cells.

✕. Patients with gastric ulcer, erosive gastritis, active upper gastrointestinal bleeding, gastric varices, or other gastric tumors.
✕. Patients who are taking or have taken proton pump inhibitors, antibiotics, glucocorticoids, nonsteroidal anti-inflammatory drugs and immunosuppressants in the last six months.
✕. People who have had gastric surgery or required gastric surgery during the study.
✕. Patients with severe systemic diseases (diseases of cardiovascular, liver, blood, kidneys, lungs or liver).
✕. Pregnant or nursing females.
✕. Patients who are reluctant to accept endoscopy and treatment.